



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT &amp; TRADEMARK OFFICE 7-80

SHEET 1 OF 1

TECH CENTER 1600/2900

FEB 14 2003

RECEIVED

**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 1252/1G348US1      SERIAL NO: 09/853,047  
 APPLICANT: SAMPATH et al.      FILING DATE: May 9, 2001  
     CONFIRMATION NO: 5094

**U.S. PATENT DOCUMENTS**

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u> <u>SUBCLASS</u>	<u>FILING DATE</u>
---------------------------	------------------------	-------------	-------------	------------------------------	--------------------

**FOREIGN PATENT DOCUMENTS**

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u> <u>SUBCLASS</u>	<u>TRANSLATION YES</u> <u>NO</u>
---------------------------	------------------------	-------------	----------------	------------------------------	----------------------------------

\*EXAMINER INITIALS

**OTHER REFERENCES  
(INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)**

1. *Zhang, R. et al., Biochemical Pharmacology, 49, 7: 929-939 (1995)*
2. *Beaton, G. et al., "Synthesis of Oligonucleotide Phosphorodithioates," Oligonucleotides and Analogues: A Practical Approach: 109-135 (IRL Press at Oxford University Press, NY 1991)*
3. *Ikehara, M. et al., "Synthesis and Properties of Oligonucleotides," Chemistry of Nucleosides and Nucleotides 1: 283-367 (1988)*

EXAMINER:

DATE CONSIDERED: 12 JUNE 2003\*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 1 OF 1  
(REV. 7-80)

REC'D  
DEC 26 2001  
TECH CENTER 1600/2000

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 1252/1G348US1      SERIAL NO: 09/853,047  
 APPLICANT: SAMPATH et al.      FILING DATE: May 9, 2001  
     CONFIRMATION NO: 5094

U.S. PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
<i>JY</i>	1. 5,614,617	03/25/97	Cook et al.	536	23.1	02/18/93

FOREIGN PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION YES</u>	<u>NO</u>
<i>JY</i>	2. 99 67378	12/29/99	WIPO	C12N	15/11	X	
<i>JY</i>	3. 94 17093	01/25/94 08/04/94	WIPO	C07H	21/00	X	

OTHER REFERENCES(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)

- \*EXAMINER INITIALS *JY* 4. IYER, R.P. et al.; "Abasic Oligodeoxyribonucleoside Phosphorothioates: Synthesis and Evaluation As Anti-HIV-1 Agents"; Nucleic Acids Research, vol. 18, 1990, pages 2855-2859.
- JY* 5. MATSUDA, A. et al.; "Nucleosides and Nucleotides. 94. Radical Deoxygenation of Tert-Alcohols in 1-(2-C-Alkylpentafuranosyl) Pyrimidines: Synthesis of (2's)-2'-C-Methylcytidine, An Antileukemic Nucleoside"; J. Med. Chem., vol. 34, 1991, pages 234-239.
- JY* 6. YOSHIMURA, Y. et al.; "Synthesis of (2's)-1-(2-C-Azidomethyl-2-Deoxy and 2-C-Cyanomethyl-2-Deoxy-Beta-D-Arabinofura Nosyl)Cytosines"; Nucleosides & Nucleotides, vol. 14, 1995, pages 427-429.
- JY* 7. BUFF, R. et al.; "2'-Deoxy-2' (S)-Ethyne Oligonucleotides; A Modification Which Selectively Stabilizes Oligoadenylate Pairing to DNA Complements"; Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 8, no. 5, March 3, 1998 (03-03-98), pages 521-521.
- JY* 8. BUFF, R., HUNZIKER, J.; "2'-Deoxy-2' (S)-Ethyne Oligonucleotides: Synthesis and Pairing Properties"; Nucleosides & Nucleotides, vol. 18, 1999, pages 1387-1388.

EXAMINER:

DATE CONSIDERED: 12 JUNE 2003\*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 1 OF 3

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT &amp; TRADEMARK OFFICE

(REV. 7-80)

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 1252/1G348US1  
APPLICANT: SAMPATH et al.SERIAL NO: 09/853,047  
FILING DATE: May 9, 2001  
CONFIRMATION NO: 5094

RECEIVED  
JAN 14 2002  
TECH CENTER 1600/2900





U.S. PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
1. 	5,741,900	4/21/98	Gmeiner et al.	536	25.31	9/11/95
2. 	5,663,321	9/2/97	Gmeiner et al.	536	25.5	6/7/95
3. 	5,614,505	3/25/97	Gmeiner et al.	514	50	9/11/95
4. 	5,457,187	10/10/95	Gmeiner et al.	536	25.5	12/8/93

FOREIGN PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION YES</u>	<u>NO</u>

\*EXAMINER INITIALSOTHER REFERENCES  
(INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

5.  J. Liu et al., "Increased Cytotoxicity and Decreased In Vivo Toxicity of FdUMP[10] Relative to 5-FU," *Nucleosides & Nucleotides* 18 (8): 1789-1802 (1999)
6.  W. Gmeiner et al., "Cyotoxicity and In-Vivo Tolerance of FdUMP[10]: A Novel Pro-Drug of the TS Inhibitory Nucleotide FdUMP," *Nucleosides & Nucleotides* 18 (6&7): 1729-1730 (1999)
7.  V.S. Bogachev, "Synthesis of Deoxynucleoside 5'-Triphosphates Using Trifluoracetic Anhydride as an Activating Reagent," *Biorganic Chemistry (Bioorg. Khim.)*, No. 9: 699-705 (1996) (Russian language article and English language abstract)
8.  F.G. Hayden, "Antimicrobial Agents: Antiviral Agents," Goodman & Gilman's, *The Pharmacological Basis of Therapeutics*, Ninth Edition: 1191-1215 (1995)
9.  P. Calabresi et al., "Chemotherapy of Neoplastic Diseases," *The Pharmacological Basis of Therapeutics*, Ninth Edition: 1225-1257 (1995)
10.  W. Gmeiner et al., "Preparation of Oligomeric 2'-Deoxy-5-Fluorouridylate of Defined Length and Backbone Composition: A Novel Pro-Drug Form of the Potent Anti-Cancer Drug 2'-Deoxy-5-Fluorouridylate," *Nucleosides & Nucleotides* 14 (1&2): 243-253 (1995)
11.  S. Crooke, "Oligonucleotide Therapeutics," *Burger's Medicinal Chemistry and Drug Discovery*, Fifth Edition, Volume 1, Chapter 21: 863-900 (John Wiley & Sons, Inc., 1995)
12.  R. Crooke et al., "*In Vitro* Pharmacokinetics of Phosphorothioate Antisense Oligonucleotides," *The Journal of Pharmacology and Experimental Therapeutics* 275, No. 1: 462-473 (1995)

BEST AVAILABLE COPY

RECEIVED

JAN 14 2002

TECH CENTER 1600/2900 SHEET 2 OF 3

13. S. Agrawal et al., "Self-Stabilized Oligonucleotides as Novel Antisense Agents," *Delivery Strategies for Antisense Oligonucleotide Therapeutics*, Chapter 7: 105-121 (CRC Press, 1995)
14. L-F Tao et al., "Uptake, Intracellular Distribution, and Stability of Oligodeoxynucleotide Phosphorothioate by *Schistosoma mansoni*," *Antisense Research and Development* 5: 123-129 (1995)
15. H. Sasmor et al., "A Practical Method for the Synthesis and Purification of <sup>14</sup>C Labeled Oligonucleotides," *Journal of Labelled Compounds and Radiopharmaceuticals* XXXVI, No. 1: 15-31 (1995)
16. V. Ravikumar et al., "Large-Scale Synthesis of oligodeoxyribonucleotide Phosphorothioate Using Controlled-Pore Glass as Support," *Nucleosides & Nucleotides* 14(6): 1219-1226 (1995)
17. A. Padmapriya et al., "Large-Scale Synthesis, Purification, and Analysis of Oligodeoxynucleotide Phosphorothioates," *Antisense Research and Development* 4: 185-199 (1994)
18. M. Andrade et al., "Efficient Synthesis of Antisense Oligodeoxyribonucleotide Phosphorothioates," *Bioorganic & Medicinal Chemistry Letters* 4 (16): 2017-2022 (1994)
19. P. Cossom et al., "Pharmacokinetics of a <sup>14</sup>C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105, after Intradermal Administration to Rats," *The Journal of Pharmacology and Experimental Therapeutics* 269 (1): 89-94 (1993)
20. M. Resmini et al., "Synthesis of arabinonucleic acid (tANA)," *Bioorg. Med. Chem. Lett.* 16 (4): 1910-1912 (1994)
21. G. Zon, "Oligonucleoside Phosphorothioates," *Methods in Molecular Biology* 20: 166-189 (Humana Press, 1993)
22. S. Beaucage, "Oligodeoxyribonucleotides Synthesis, Phosphoramidite Approach," *Methods in Molecular Biology* 20: 33-47 (Humana Press, 1993)
23. B. Froehler, "Oligodeoxynucleotide Synthesis, H-Phosphonate Approach," *Methods in Molecular Biology* 20: 63-71 (Humana Press, 1993)
24. M. Resmini et al., "Synthesis of Arabinonucleoside Phosphoramidite Building Blocks," *Helvetica Chimica Acta* 76: 158-167 (1993)
25. D.W. Hutchinson, "The Synthesis, Reactions and Properties of Nucleoside Mono-, Di-, Tri-, and Tetraphosphates and Nucleotides with Changes in the Phosphoryl Residue," *Chemistry of Nucleosides and Nucleotides* 2: 81-93 (1991)
26. G. Hoke et al., "Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection," *Nucleic Acids Research* 19 (20): 5743-5748 (1991)
27. G. Beardsley et al., "Chemical synthesis of DNA oligomers containing cytosine arabinoside," *Nucleic Acids Res.* 16 (19): 9165-9176 (1988)
28. P. Giannaris et al., "Hybridization properties of oligoarabinonucleotides," *Can. J. Chem.* 73 (3): 909-918 (1994)
29. R. Jones, "Preparation of Protected Deoxyribonucleosides," *Oligonucleotide Synthesis: A Practical Approach*: 23-34 (Oxford University Press, 1984).
30. M. Chapekar et al., "Cordycepin Analog of (A2'p)<sub>2</sub>A: Evidence That It Functions as a Prodrug of Cordycepin," *Biochemical and Biophysical Research Communications* 115 (1): 137-143 (1983).
31. K. Ogilvie et al., "The preparation of protected arabinonucleosides," *Can. J. Chem.* 61 (6): 1204-1212 (1983).
32. L. Dudycz et al., "Mechanism of Methylation of Nucleoside Sugar Hydroxyl Groups by Diazomethane in the Presence of Stannous Chloride," *Carbohydrate Research* 91: 31-37 (1981)
33. R. Lipnick et al., "A Comparative Conformational Study of Certain 2'-Deoxy-2'-Fluoro-Arabinofuranosylcytosine Nucleosides," *Biochimica et Biophysica Acta* 608: 96-102 (1980)
34. J. Beranek et al., "Synthesis of araC," *Nucl. Acid Chem.* 1: 249-254 (1978)
35. J. Montgomery et al., "The 2-O-Methyl Ether of 1-β-D-Arabinofuranosylcytosine," *Journal of Medicinal Chemistry* 17 (3): 360-363 (1974)
36. J. Kusmierenk et al., "Preparation of O'-Alkyl Derivatives of Cytosine and Uracil Nucleosides," *Biochemistry* 12 (2): 194-200 (1973)
37. E. Darzynkiewicz et al., "O'-Methyl Derivatives of Arabinosylcytosine," *Biochemical and Biophysical Research Communications* 46 (4): 1734-1740 (1972)

BEST AVAILABLE COPY

RECEIVED

JAN 14 2002

TECH CENTER 1600/2900 SHEET 3 OF 3

38 *JJ* E. Darzynkiewicz et al., "O'-Alkyl Derivatives of 1- $\beta$ -D-Arabinofuranosylcytosine," *Nucl. Acid Chem.* 1, 239-248 (1978)

EXAMINER: *Jayne L. Jay* DATE CONSIDERED: 12 June 2003

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

::ODMA\WORLDOXM\1252\1G348US1\LWJ6820.WPD

BEST AVAILABLE COPY